Clinical trial NCT01095744: Influence of Age on Amyloid Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease
Official title: Influence of Age on amyloïd Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease Like Posterior Cortical Atrophy (PCA) and Logopenic Progressive Aphasia (LPA)Using Positron Emitting Tomography (PET) Imaging
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Alzheimer's Disease
Posterior Cortical Atrophy
Logopenic Progressive Aphasia
Keywords: PIB imaging,
brain atrophy
cognitive impairment
Pet imaging
Alzheimer's disease
amyloid protein
Lead sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Sponsor class: OTHER_GOV
First posted: 2010-03-30
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients have to fulfil criteria for (1)AD with an amnesic syndrome of the media-temporal type, EOAD have lower frequency and (2) and for atypical Ad respecting episodic memory, inaugural language disorder or visual-spatial disorder

Brief summary: The first objective is to asses influence of age on amyloid load measured by PET imaging using Pittsburgh B compound (PiB) radio-tracer, in Alzheimer's disease(AD). This will allow the determination of brains age-specific deterioration factors by comparing Early onset AD (EOAD), Late onset AD (LOAD)and atypical focal cortical AD (PCA and LPA). The amount of brain lesions in AD patients is estimated by:

1. measuring the rate of cortical brain atrophy,
2. FDG imaging of glucose metabolism reflecting neuronal activity, and
3. for patients who benefited from a lumbar puncture; Cortical-spinal fluid (CSF) amounts of amyloïd and tau proteins are measured.

Detailed description: Literature data suggests there are different types of AD depending on their age of onset, called EOAD and LOAD. These two categories are distinguished by the localization of brain atrophy : severe and 'posterior' in EOAD and more 'anterior' in LOAD. Neuro-pathologic data suggests some atypical focal cortical atrophy, characterized by a respect of episodic memory, may be classified within EOAD.

PiB-based PET imaging allows the in-vivo visualization and quantification of amyloïd load.

We want to answer the question whether the amount of amyloïd protein may be lower in LOAD than EOAD in patients showing the same level of dementia, and thus identify ageing-specific cognitive disorders and understand witch factors influence etio-pathology of typical and atypical Alzheimer's disease.

Eligibility criteria: Inclusion Criteria:

* AD patients: clinical dementia rating between 0.5 and 2 free and cued recall test (Grober and Buschke) cued-recall \< 18/48 and total recall \< 40/48
* atypical AD : i visual-spatial disorder and respect of episodic memory progressive evolution, Balint syndrome ii progressive language disorder constituted of logopenic aphasia respect of episodic memory
* controls: age over 30 MMSE over or equal to 27 normal neuropsychiatric state for age and education level

Exclusion Criteria:

* for every patients : psychiatric disorders age under18 absence of social security counter indication to MRI supposed or actual alcoholism or drug addiction pregnancy

Primary outcomes:
measure: PIB-PET imaging of amyloid load
timeFrame: 0 - 2 months
measure: FDG-PET imaging of glucose metabolism
timeFrame: 0 - 2 months
measure: clinical phenotypic assessment
timeFrame: 0 - 2 months
measure: MRI
timeFrame: 0 - 2 months
measure: ApoE gene sequencing
timeFrame: 0 - 24 months after inclusion
Secondary outcomes:
measure: amyloid and Tau measurements in cerebro-spinal fluid (csf)
timeFrame: -6 months or +6months arround T0
Other outcomes:
Locations:
city: Paris
country: France
facility: Pitie Salpêtrière Hospital
state: Ile de France
Study officials:
affiliation: INSERM U975
name: Bruno Dubois, professor doctor
role: PRINCIPAL_INVESTIGATOR
affiliation: Inserm U975
name: marie c sarzin, doctor
role: STUDY_CHAIR
References: